Research progress in PCSK9 and lipid lowering drugs
ZHANG Wei
ZHOU Bing-yang
GUO Yuan-lin
LI Jian-jun
Abstract：Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel circulating protein,which plays an important role in the regulation of cholesterol metabolism.Over the past decade,experimental and clinical studies have established that over-or poor expression of PCSK9 has a key impact not only on circulating PCSK9 and low density lipoprotein cholesterol (LDL-C) levels but also on cardiovascular risk and atherosclerotic process.Since the first discovery of PCSK9-related gene in 2003,factors that can influence circulating PCSK9 concentration are of great interest in a variety of medical fields,especially in pharmacology.In this review we focus on the impact of lipid-lowering drugs on circulating PCSK9 concentration and its clinical implications in order to provide new considerations for optimizing current strategies with regard to cholesterol control.
Keywords：proprotein convertase subtilisin/kexin type 9low-density lipoprotein cholesterollipid profilelipid-lowering drugpharmacologic actions
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：8( 1016-1023 )